GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Inventories, Other

ARCA biopharma (FRA:HQ10) Inventories, Other : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. ARCA biopharma's other inventories for the quarter that ended in Jun. 2024 was €0.00 Mil.


ARCA biopharma Inventories, Other Historical Data

The historical data trend for ARCA biopharma's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Inventories, Other Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ARCA biopharma Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines